Discovery of a druggable pocket in SARS-CoV-2 Spike: New avenue to defeat COVID-19?


REGISTER FREE NOW:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)

  Register

Discovery of a druggable pocket in SARS-CoV-2 Spike: New avenue to defeat COVID-19?


Overview

Facebook icon Twitter iconLinkedIn icon

COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Key to SARS-CoV-2 therapeutic development is to unravel the mechanisms driving high infectivity, broad tissue tropism and severe pathology. SARS-CoV-2 is decorated by multiple copies of a glycoprotein, called Spike, which is key to such severe infectivity.

Using cryo-electron microscopy and cloud computing, Dr. Imre Berger has discovered a potentially druggable pocket within the SARS-CoV-2 Spike, which appears to be present in the highly pathogenic coronaviruses that caused previous SARS and MERS outbreaks

Watch this webinar to find out for the first time the structural link between COVID-19 pathology and the virus itself, setting the stage for developing new therapeutic interventions to combat and defeat COVID-19.

Key learning objectives:
Learn about the high-tech science technologies and techniques being used to defeat the global COVID-19 epidemic.

Who should attend?

  • COVID19 researchers
  • R&D scientists in academia and industry
  • Biologists
  • Biochemists
  • Those working within CROs and CDMOs
  • Drug developers

Certificate of attendance
All webinar participants can request a certificate of attendance, and a learning outcomes summary document for continuing education purposes.


Presenters

Presenter
Imre Berger
Founder and Managing Director
Max Planck Bristol Centre for Minimal Biology
View Biography
Presenter
Dr. Carrie Haslam
Associate Editor
SelectScience
View Biography